Yun Kyu Kim

Yun Kyu Kim

Auto-generated profile, based on publicly available information

Yun Kyu Kim

Asan Institute of Life Sciences, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
EKEun Hye Kim
Eun Hye Kim
SPSangwoo Park
Sangwoo Park
YKYun Kyu Kim
Yun Kyu Kim
MMMinwoo Moon
Minwoo Moon
JPJeongwon Park
Jeongwon Park
Young-Pil KimYoung-Pil Kim
Young-Pil Kim
Despite the potential of photodynamic therapy (PDT), its comprehensive use in cancer treatment has not been achieved because of the nondegradable risks of photosensitizing drugs and limits of light penetration and instrumentation. Here, we present bioluminescence (BL)–induced proteinaceous PDT (BLiP-PDT), through the combination of luciferase and a reactive oxygen species (ROS)–generating protein (Luc-RGP), which is self-luminescent and degradable. After exposure to coelenterazine-h as a substrate for luciferase without external light irradiation, Luc-RGP fused with a small lead peptide–induced breast cancer cell death through the generation of BL-sensitive ROS in the plasma membrane. Even with extremely low light energy, BLiP-PDT exhibited targeted effects in primary breast cancer cells from patients and in in vivo tumor xenograft mouse models. These findings suggest that BLiP-PDT is immediately useful as a promising theranostic approach against various cancers.

1 January 2020 in Journal of Korean Medical Science
Verified
Journal Article
Open access
PDF file
GPGil-Chun Park
Gil-Chun Park
SHShin Hwang
Shin Hwang
MKMyoung-Soo Kim
Myoung-Soo Kim
DJDong-Hwan Jung
Dong-Hwan Jung
GSGi-Won Song
Gi-Won Song
YKYun Kyu Kim
Yun Kyu Kim
Park GC, et al. J Korean Med Sci. 2020 Jan;35(6):e36. https://doi.org/10.3346/jkms.2020.35.e36

1 January 2022 in Annals of Surgical Treatment and Research
Verified
Journal Article
Open access
PDF file
SHShin Hwang
Shin Hwang
KLKyung jin Lee
Kyung jin Lee
DMDeok-Bog Moon
Deok-Bog Moon
GSGi-Won Song
Gi-Won Song
DJDong-Hwan Jung
Dong-Hwan Jung
SLSung-Gyu Lee
Sung-Gyu Lee
Hwang S, et al. Ann Surg Treat Res. 2022 Jan;102(1):46-54. https://doi.org/10.4174/astr.2022.102.1.46

1 January 2020 in Immune Network
Verified
Journal Article
Open access
PDF file
YKYun Kyu Kim
Yun Kyu Kim
SCSoo Chul Chae
Soo Chul Chae
HYHun Ji Yang
Hun Ji Yang
DADa Eun An
Da Eun An
SLSion Lee
Sion Lee
KLKyung jin Lee
Kyung jin Lee
Kim YK, et al. Immune Netw. 2020 May;20(3):e26. https://doi.org/10.4110/in.2020.20.e26

30 April 2021 in Medicine
Verified
Journal Article
Open access
BNByeong-Gon Na
Byeong-Gon Na
YKYun Kyu Kim
Yun Kyu Kim
SHShin Hwang
Shin Hwang
KLKyung jin Lee
Kyung jin Lee
GPGil-Chun Park
Gil-Chun Park
SLSung-Gyu Lee
Sung-Gyu Lee
Programmed death protein 1 (PD-1) pathway is one of the most critical mechanisms in tumor biology of hepatocellular carcinoma (HCC). The study aimed to assess the prognostic influence of pretransplant serum soluble PD-1 (sPD-1) in patients undergoing liver transplantation for treatment of HCC. Data from 229 patients with HCC who underwent living donor liver transplantation between January 2010 and December 2015 were retrospectively evaluated. Stored serum samples were used to measure sPD-1 concentrations. Overall survival (OS) and disease-free survival (DFS) rates were 94.3% and 74.5% at 1 year; 78.2% and 59.2% at 3 years; and 75.4% and 55.5% at 5 years, respectively. Prognostic analysis using pretransplant serum sPD-1 with a cut-off of 93.6 μg/mL (median value of the study cohort) did not have significant prognostic influence on OS (P = .69) and DFS (P = .26). Prognostic analysis using sPD-1 with a cut-off of 300 μg/mL showed similar OS (P = .46) and marginally lower DFS (P = .070). Combination of Milan criteria and sPD-1 with a cutoff of 300 μg/mL showed similar outcomes of OS and DFS in patients within and beyond Milan criteria. Multivariate analysis revealed that only Milan criteria was an independent prognostic for OS and DFS, but pretransplant sPD1 with a cut-off of 300 μg/mL did not become a prognostic factor. The results of this study demonstrate that pretransplant serum sPD-1 did not show significant influences on post-transplant outcomes in patients with HCC. Further large-scale, multicenter studies are necessary to clarify the role of serum sPD-1 in liver transplantation recipients.

5 September 2025 in Clinical Transplantation and Research
Verified
Journal Article
Open access
PDF file
SHShin Hwang
Shin Hwang
HKHyo Jung Ko
Hyo Jung Ko
ETEunyoung Tak
Eunyoung Tak
KLKyung jin Lee
Kyung jin Lee
YLYun-Kyu Lee
Yun-Kyu Lee
Shin Hwang, Hyo Jung Ko, Eunyoung Tak, Kyoung-Jin Lee, Yun-Kyu Lee. Clin Transplant Res -0001;0:. https://doi.org/10.4285/ctr.25.0027